Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.62 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7496788 | 1.00 | SYK (0.62) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL18939366 | 0.90 | SYK (0.60) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL18939364 | 0.90 | SYK (0.60) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL3276799 | 0.90 | SYK (0.59) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL7360205 | 0.90 | CTRB1 (0.62) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL25301720 | 0.90 | SYK (0.62) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL1262680 | 0.90 | SYK (0.59) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL25256638 | 0.90 | SYK (0.62) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL3108565 | 0.90 | SYK (0.59) | SYKCTRB1CTSKATMCTSL | |
| SCHEMBL7360200 | 0.90 | CTRB1 (0.62) | SYKCTRB1CTSKATMCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4010314-B1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240002397-A1 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230365533-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365533-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4247801-A1 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4200295-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-06-28 | — | — | EP | disclosed |
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-20 | — | — | US | disclosed |
| CN-116249697-A | Bicycloheptane pyrrolidine orexin receptor agonists | 默沙东有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022040070-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220056017-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3130608-B1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| EP-1340756-B1 | NOVEL BETA-LACTAM COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7163936-B2 | β-lactam compounds and process for producing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040102433-A1 | Novel beta-lactam compounds and process for producing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102433-A1 | Novel beta-lactam compounds and process for producing the same | MRPL21, MCRS1, RPS4X | SYK 2797/4885CTRB1 941/4885CTSK 2383/4885 |
| US-20230365533-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | SYK 4351/4885CTRB1 1454/4885CTSK 1907/4885 |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | SYK 2786/4885CTRB1 2368/4885CTSK 2204/4885 |
| US-20240002397-A1 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, OXTR | SYK 2623/4885CTRB1 3436/4885CTSK 1609/4885 |
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | HCRTR1, HCRTR2, CRHR1 | SYK 4230/4885CTRB1 1666/4885CTSK 1594/4885 |
| US-20220056017-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | SYK 4230/4885CTRB1 1666/4885CTSK 1594/4885 |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, OXTR | SYK 3121/4885CTRB1 3039/4885CTSK 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.